Momentum Public Relations
Press Release: February 28 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is reporting on an operational update and areas of investment for financial Q2 2018 (October 1, 2017 to December 31, 2017).
Aurelio Useche, President and CEO of Relevium stated: “The integration, optimization and scale up of BioGanix since acquisition has gone as expected.” Mr. Useche continued: “Operationally we expected a learning curve and expected to overcome all challenges. I think the Operations Team has overcome all challenges and the Company is poised to drive growth in the 2018 calendar year. The e-commerce landscape for nutraceuticals is under constant change and we have been quick on our feet to adapt and maintain sales velocity.”
During the first six (6) months of operating BioGanix, the Company has focused on transitioning the business, accounts and assets. Following the successful transition which lasted until roughly November 1, 2017, the Company built up an internal Operations Team which subsequently set forth to optimize the business predominantly through conceptualization and deployment of the Mach 2.0 Marketing Engine. During this period, the Company did experience a temporary decrease in revenue.
Since October 1, 2017 the Company has invested over CAD $250,000 for building out the infrastructure and acquiring the talent necessary to drive future growth of the BioGanix brand. These investments in technology, people and commercial agreements will also be integral in allowing the Company to execute on the plethora of product and brand launches it has planned for the 2018 calendar year.
The Company expects to launch no less than three (3) new brands and over twenty (20) new products or SKUs in 2018. Launches will begin as soon as March 2018. The Company will provide further detail to this effect in a forthcoming news release.
Mr. Abis Hussain, Senior Marketing Officer of Relevium Technologies: “We are really excited to start launching products. The Company has yet to launch products that fully reflect our collective efforts. The products that we will bring to market this year will really show our ability to find and market exclusive products. Prior to this, everything being marketed was part of the classic line launched by the previous BioGanix team. We believe our true colors and grit are about to shine.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Relevium Technologies Inc. has provided further clarifications on its press release from earlier on Feb. 23, 2018.
The company has received several requests from active shareholders to clarify ambiguity in the language of the operational press release from earlier in the day.
Aurelio Useche, president and chief executive officer of Relevium, stated, “The company is very appreciative of the feedback from its shareholders who asked us to provide clarity over the press release.”
The first six months of operations have been successful in all fronts, including sales revenue, which have continued to demonstrate an overall positive direction ahead of previous periods.
The company did highlight in the previous news release a revenue decline, which was in reference to the month of November. The decline was related to product adjustments and changes in marketing costs due to the implementation of the automation process. However, overall revenues for the six-month period were on target.
The following is a summary of the message that was intended by the company to communicate to shareholders:
- The integration, optimization and scale-up of BioGanix since acquisition have been successful and as expected. The transition period included an expected learning curve, and the operating team has done very well in meeting the challenge.
- Sales revenues are on target and ahead of last year’s results by the previous ownership.
- The company has made several important investments, not only to optimize current operations, but also to prepare the team for organic and acquisition-based growth.
The following were also important updates management felt key to convey to its shareholder base:
- The eventual launch of three new brands, the culmination of the successful exclusivity agreements entered into by the company during the reporting;
- The launch of over 20 new products or SKUs (stock-keeping units) in 2018 expected to hit the shelves as soon as March, 2018.
Management looks forward to reporting Q2 2018 financial results next week.